"Emerging Market stock" Gongwin-KY was approved as a Biotech And New Pharmaceuticals Company, planning to launch its IPO plan
Gongwin-KY (6617) was approved by the Ministry of Economic Affairs to be a Biotech And New Pharmaceuticals company, and will launch its IPO plan based on its scheduled timetable. Gongwin stated that it has received the official document No. 10620432510 from the Ministry of Economic Affairs, validating that its new anti-cancer drug PTS100 for primary liver cancer is in line with relevant provisions in Article 3, Paragraph 2 of the Biotech and New Pharmaceutical Development Act, thus the Company is approved to be a Biotech and New Pharmaceutical Company and will launch its IPO plan according its scheduled timetable.
Gongwin-KY stated that its liver cancer new drug PTS100 is administered via a new "minimally invasive targeted chemical ablation therapy" technology, which means that the liver cancer new drug PTS100 has selective targeting properties among cancer cells and normal cells. A tiny guiding probe is used to directly inject the drug into the tumor and the surrounding tissues of the tumor, to achieve the effect of Chemo-Ablation and to cause the necrosis of cancer cells in the local area. This achieves the effects of the smallest wound caused by surgery as well as selectively killing cancer cells, providing current liver cancer patients another treatment approach with more advantages.
News link URL：https://www.chinatimes.com/realtimenews/20171207003265-260410?chdtv
News&Media